PBR Staff Writer Published 27 October 2014

Bayer HealthCare has signed a two-year collaboration agreement with Kyoto Universitys Office of Society-Academia Collaboration for Innovation (KU-SACI) in Japan to jointly discover candidates for possible collaborative research projects.

Under the deal, the two parties will focus on key areas of unmet medical need such as cardiology, oncology, hematology, gynecology and ophthalmology, by combining Kyoto University's expertise and innovative approaches in diverse research areas with Bayer's expertise in drug discovery and development.

The deal is part of Bayer's aim to collaborate with external partners from academia and industry to develop new treatments for patients across the world.

The company has recently entered into strategic research alliance in the area of gynecological therapies with the University of Oxford as well as with Dimension Therapeutics to develop and commercialize new gene therapy to treat hemophilia A.

In addition, the company has established two research incubators for young life sciences companies in the context of its open innovation approach.

The joint effort will be supported by Bayer's newly established Open Innovation Center Japan (ICJ) in Osaka, Japan.

The threefold mission of the KU-SACI is to promote collaborative research among academia, industries and the government; manage and use the university's intellectual properties through licensing & research collaboration with industries; as well as to support business start-ups by university researchers or students.

Image: Bayer and KU-SACI members during signing of the agreement. Photo: courtesy of Bayer HealthCare AG.

Read the original here:
Bayer, Kyoto University partner on collaborative research projects

Comments are closed.